Showing 4681-4690 of 8205 results for "".
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- Skin Diseases Highly Common in Older Adultshttps://practicaldermatology.com/news/skin-diseases-highly-common-in-older-adults/2460507/Fully 80 percent of adults aged 70 to 93 have at least one skin disease that required treatment, and the most common conditions were fungal skin infections, rosacea, actinic keratosis, and eczema, according to a new study in the 
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu
- Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatologyhttps://practicaldermatology.com/news/verrica-enters-agreement-with-lytix-for-oncolytic-peptide-for-dermatology/2460498/Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinoma
- Galderma Gives Back: Company Donates 1,200 Backpacks Filled with School Supplies to Northwest ISD Studentshttps://practicaldermatology.com/news/galderma-gives-back-company-donates-1200-backpacks-filled-with-school-supplies-to-northwest-isd-students/2460495/For the fifth consecutive year, Galderma donated backpacks filled with school supplies to Northwest Independent School District (NISD) students. This year, Galderma donated 1,200 backpacks for students in grades Kindergarten through 12, for a total of 6,105 backpacks donated since 2016.
- Early Study Demonstrates Roflumilast cream Safe and Effective for Chronic Plaque Psoriasishttps://practicaldermatology.com/news/early-study-demonstrates-roflumilast-cream-safe-and-effective-for-chronic-plaque-psoriasis/2460493/Arcutis Biotherapeutics, Inc. shared positive results from a Phase 1/2a trial of its investigational drug topical roflumilast cream for the treatment of chronic plaque psoriasis that were published in the August issue of the Journal of Drugs in Dermatology. The results demonstrate that ARQ-151 (r
- New Data Supports the Safety and Efficacy of Dupixent in Adults and Children with ADhttps://practicaldermatology.com/news/new-data-supports-the-safety-and-efficacy-of-dupixent-in-adults-and-children-with-ad/2460492/Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. In the Phase 3 LIBERTY AD pediatric trial data, nearly three times as many children achieved clear or almost clear skin when treated with Du
- New Dermatology Atlas to Highlight and Compare Features of Common Dermatologic Conditions in Different Skin Typeshttps://practicaldermatology.com/news/new-dermatology-atlas-to-highlight-and-compare-features-of-common-dermatologic-conditions-in-different-skin-types/2460491/Leaders from academic dermatology and education are joining together to create a comprehensive dermatology atlas to address what they say has become a well-documented gap in dermatology education. The atlas will display side-by-side images of the most common dermatology conditions in the full spe
- FDA Fast Tracks Leo Pharma’s Delgocitinib Cream for Hand Eczemahttps://practicaldermatology.com/news/fda-fast-tracks-leo-pharmas-delgocitinib-cream-for-hand-eczema/2460490/Delgocitinib cream, Leo Pharma’s investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are curr